← FDA DRUG APPROVALS

FDA ANDA · ANDA078800

TENOFOVIR DISOPROXIL FUMARATE

Sponsor: CIPLA

APPLICATION
ANDA078800
TYPE
ANDA
ORIGINAL APPROVAL
2018-01-26
LATEST ACTION
2019-11-19
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

TENOFOVIR DISOPROXIL FUMARATEPrescription
TENOFOVIR DISOPROXIL FUMARATE 300MG · TABLET · ORAL

Approval history

2019-11-19Labeling · Supplement 19 · standardAP
2019-11-19Labeling · Supplement 17 · standardAP
2019-11-19Labeling · Supplement 18 · standardAP
2019-11-19Labeling · Supplement 20 · standardAP
2018-01-26UNKNOWN · Original · standardAP
2018-01-26OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →